Recursion Pharmaceuticals, Inc. (RXRX) Earnings Call Analysis

NASDAQ · Unknown · Unknown

8/25

Growth 2 Margin 0 Expansion 4 Platform 2 Financial 0

latest quarter score

Earnings Reports

8
Recursion Pharmaceuticals (RXRX) Q2 2026: Three Clinical Programs Advance, Platform Delivers First Patient Dosing
August 05, 2026
15
Recursion (RXRX) Q1 2026: 35% Operating Cost Cut Extends Runway to 2028, Platform Speed Surges
May 06, 2026
15
Recursion (RXRX) Q4 2025: 35% OpEx Cut Extends Runway, AI Platform Delivers First Clinical Proof
February 25, 2026
12
Recursion (RXRX) Q3 2025: $200M Expense Cut Locks in 2027 Runway, Platform Leverage Accelerates
November 06, 2025
15
Recursion (RXRX) Q2 2025: Cash Burn Cut 35% as Platform Drives Pipeline and Partner Milestones
August 06, 2025
19
Recursion (RXRX) Q1 2025: Pipeline Refocus Trims $150M Cash Burn, Prioritizes AI-Driven Oncology Bets
July 07, 2025
Recursion (RXRX) Q4 2024: Platform Synergies Drive 60% Reduction in Hit-to-Lead Timelines
February 28, 2025

Browse all companies